NCT07635914尚未招募3 期
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of Aprocitentan Tablets in the Treatment of Resistant Hypertension
适应症
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 入组人数
- 382
研究概览
简要总结
Aprocitentan tablets are currently the only endothelin dual receptor antagonist approved internationally for the treatment of resistant hypertension.This is a multicenter, randomized, double-blind, placebo-controlled Phase 3 study to evaluate the efficacy and safety of aprocitentan tablets(SYH9108) in patients with treatment-resistant hypertension (rHTN)
详细描述
The study consists of a screening period (up to 2 weeks), a run-in period (4 weeks), a treatment period (8 weeks), and a follow-up period. During the study, all participants should continue their background antihypertensive medications (at the same agents and dosages as used within 4 weeks prior to screening) and maintain lifestyle interventions such as a low-salt diet.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female participants must be ≥18 years of age.
- •Participants must have received stable doses of ≥3 antihypertensive agents from distinct pharmacological classes for at least 4 weeks prior to signing the ICF, with such therapy maintained until randomization.
- •During the screening period and prior to randomization, SiSBP ≥140 mmHg with or without SiDBP ≥90 mmHg, and SiSBP <180 mmHg and SiDBP <110 mmHg.
- •Participants are able to understand and cooperate in completing this trial, voluntarily participate in the trial, and sign the Informed Consent Form (ICF).
排除标准
- •Presence of secondary hypertension.
- •Have had transient ischemic attack, stroke, unstable angina pectoris, or acute myocardial infarction occurring within the period from 12 months prior to signing the ICF up to randomization.
- •From screening to prior to randomization, have presence of uncontrolled severe disease or life-threatening disease, or failure to recover from major surgery, or prior thyroid surgery, or presence of malignant tumor, or meeting the criteria for severe hepatic insufficiency at screening.
- •Have had unstable cardiac disease occurring within the period from 6 months prior to signing the ICF up to randomization.
- •Have received dialysis at any time prior to signing the ICF or prior to randomization.
- •Type 1 diabetes.
- •Compliance with any background antihypertensive drug or placebo is <80% or >120% during the run-in period.
- •Use of endothelin receptor antagonists, antihypertensive drugs other than background medications, or other blood pressure-affecting drugs, or high-dose loop diuretics from 4 weeks prior to signing the ICF until randomization; or use of oligonucleotide antihypertensive agents within 1 year prior to signing the ICF.
- •Hypersensitivity or suspected hypersensitivity to the excipients of the investigational product, endothelin receptor antagonists, or background antihypertensive drugs, or potential hypersensitivity to the investigational product.
- •Participated in other clinical trials and received at least one dose of study treatment within 12 weeks prior to signing the ICF.
- •Average night shifts are ≥ 2 times per week during the 4 weeks prior to signing the ICF, the screening period, the run-in period, or the anticipated study period.
- •History of drug abuse or alcohol abuse within 5 years prior to signing the ICF.
- •Any of the following test results during the screening period or prior to randomization:
- •1) BMI≥37.5 kg/m
- •Hemoglobin < 100 g/L; 3) NT-proBNP ≥ 500 pg/mL; 4) QTcF: > 450 ms in males, > 470 ms in females; 5) eGFR < 15 mL/min/1.73 m²; 6) ALT or AST > 3 × ULN, or total bilirubin > 1.5 × ULN; 7) HbA1c > 8.0%; 8) TSH outside the normal range and FT3 and/or FT4 outside the normal range; 9) Positive HBsAg and positive HBV-DNA, or positive for any of anti-HCV antibody, anti-HIV antibody, anti-Treponema pallidum antibody.
- •14. Female participants of childbearing potential who are pregnant, breastfeeding, or have a positive pregnancy test from signing the ICF until randomization; or female participants of childbearing potential and male participants who plan to conceive (including sperm or egg donation) and/or are unable to use effective contraceptive methods during the study period and within 30 days after the end of treatment.
研究者
相似试验
招募中
3 期
A Study of the Efficacy and Safety of BCD-281 in Patients With Relapsing-Remitting Multiple SclerosisNCT07321093Biocad292
招募中
1 期
A Single Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of SYH2085NCT07412353CSPC ZhongQi Pharmaceutical Technology Co., Ltd.74
尚未招募
2 期
A Multicenter Phase 2a Clinical Study to Evaluate SIM0278 in Subjects With Active Lupus NephritisLupus NephritisNCT07393451Simcere Pharmaceutical Co., Ltd60
招募中
1 期
Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HT31-1 for Treating ARDSNCT07449572HTIC, Inc24
招募中
2 期
Study to Assess Efficacy and Safety of HSK39297 Tablets in Patients With LNNCT07363460Haisco Pharmaceutical Group Co., Ltd.105